Clinical trials: Primary Hypertension
Essential Hypertension
Personal Activity Intelligence in the Treatment of High Blood Pressure
Personal Activity Intelligence (PAI) is a novel metric developed to quantify the amount of routine physical activity (PA) needed to improve health and reduce cardiovascular (CV) mortality.
- Trial name
- NCT04151537
- Testing
- Personal Activity Intelligence, Physical Activity Guidelines
- Where
- Norway
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Primary Hypertension
Nijmegen Antihypertensive Management Improvement Study
High blood pressure is an important risk factor for diseases of heart and blood vessels like myocardial infarction and stroke. Many patients are not treated to target blood pressures, even though good blood pressure lowering…
- Trial name
- NAMIS (NCT00457483)
- Testing
- hydrochlorothiazide, valsartan, 80 mg once-a-day
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- Radboud University Medical Center
Hypertension
Mobile Application to Improve Nutritional Counseling Provided by Primary Care Physicians for Hypertension.
The purpose of this study is to investigate whether the use of a mobile app could improve knowledge and practice in nutrition counseling performed by primary care physicians in Brazil.
- Trial name
- NCT02249494
- Testing
- telehealth, nutritional counseling, smartphone (mobile app)
- Where
- Brazil
- Volunteers
- 110 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Essential Hypertension
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
This study is to compare the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination and Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients with Essential Hypertension…
- Trial name
- NCT06041529
- Testing
- Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
- Where
- 15 sites in South Korea
- Volunteers
- 198 people
- Sponsor
- Yuhan Corporation
Essential Hypertension
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.
- Trial name
- NCT06716970
- Testing
- QR12000 75mg, QR12000 150mg, Sacubitril/valsartan 200mg
- Where
- China
- Volunteers
- 810 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Primary Open Angle Glaucoma
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
This clinical trial is a prospective, randomized, controlled, multicenter, study. After informed consent is obtained, patients will be evaluated for eligibility based on glaucoma severity, eye health, and visual acuity.
- Trial name
- NCT01539239
- Testing
- Hydrus Aqueous Implant, Cataract surgery
- Where
- 38 sites in United States, Canada and 7 more
- Volunteers
- 1,143 people
- Sponsor
- Ivantis, Inc.
Cirrhosis, Esophageal Varices
Carvedilol Plus EVL or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders
The goal of this clinical trial is to evaluate whether carvedilol plus endoscopic variceal ligation (EVL) is more effective for the primary prevention of esophageal variceal bleeding than carvedilol alone in carvedilol…
- Trial name
- CVL-NR (NCT06594783)
- Testing
- Carvedilol plus endoscopic variceal ligation, Carvedilol alone
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Ocular Hypertension
Efficacy Comparison of Xalatan and Azopt on POAG and OH
Prostaglandin analogs (PGAs) represent a new class of active ocular hypotensive agents and possess a unique mechanism of action.
- Trial name
- NCT01084902
- Testing
- Latanoprost, Brinzolamide
- Volunteers
- 130 people
- Sponsor
- Peking University First Hospital
Hypertension
Doxazosin and Ramipril in Hypertension
Randomized double-blind parallel group study in patients with mild-to-moderate hypertension to evaluate the effects beyond the blood pressure lowering effect of treatment for 12 weeks with ramipril or doxazosin on hemostatic…
- Trial name
- DoRa (NCT02901977)
- Testing
- Ramipril, Doxazosin
- Where
- Sweden
- Volunteers
- 71 people
- Sponsor
- Karolinska Institutet
Essential Hypertension
Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone in reducing blood pressure.
- Trial name
- NCT01122251
- Testing
- Lercanidipine + Valsartan, Lercanidipine or Valsartan
- Where
- 2 sites in South Korea
- Volunteers
- 441 people
- Sponsor
- LG Life Sciences
Glaucoma
Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?
Matrix metalloproteinases (MMPs) fulfill diverse important molecular functions and play pivotal roles in development, tissue morphogenesis, repair, aging, and inflammatory processes.
- Trial name
- NCT00312403
- Testing
- Blood Sample
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Treatment Outcome
Effect of Latanoprost on Optic Nerve Perfusion
46 eyes of 23 patients have been treated with topical Latanoprost 0.005 %. visual field was performed on all eyes. NFLT was measured using OCT. Radial peripapillary capillary (RPC) vascular density was measured using OCTA .
- Trial name
- NCT06629129
- Testing
- Latanoprost (0.005%)
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Zagazig University
Essential Hypertension
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension
The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs hydrochlorothiazide when each is used with azilsartan medoxomil, once daily (QD), in participants with moderate to severe essential…
- Trial name
- NCT00818883
- Testing
- Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and hydrochlorothiazide
- Where
- 53 sites in United States, Russia
- Volunteers
- 609 people
- Sponsor
- Takeda
Uncontrolled Hypertension
Netrod-Pilot Study of Renal Denervation With NetrodTM Sixelectrode Radiofrequency RDN System
This single-arm, non-randomized, open-label investigation aims to collect safety and efficacy data of the CE-Marked Netrod™ RDN System in treating European patients with primary hypertension in the absence of anti-hypertensive…
- Trial name
- NCT07061054
- Testing
- Netrod™ six-electrode radiofrequency renal denervation system
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Hypertension
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.
- Trial name
- NCT01415531
- Testing
- Nebivolol
- Where
- 75 sites in United States
- Volunteers
- 641 people
- Sponsor
- Forest Laboratories
Glaucoma, Primary Open Angle
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple pre-clinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like glaucoma.
- Trial name
- NCT01408472
- Testing
- NT-501 CNTF Implant
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jeffrey L Goldberg
Glaucoma, Open-Angle, Ocular Hypertension
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).
- Trial name
- NCT01594970
- Testing
- Bimatoprost 0.01%
- Where
- South Korea
- Volunteers
- 800 people
- Sponsor
- Allergan
Glaucoma, Angle-closure
Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle - Closure
This study was to evaluate the efficacy and safety of immediate anterior chamber paracentesis (ACP) with a 30-gauge needle as an initial treatment for acute primary angle closure (APAC).
- Trial name
- NCT01923454
- Testing
- Paracentesis, Acetazolamide, Peripheral iridotomy
- Where
- Thailand
- Volunteers
- 15 people
- Sponsor
- Siriraj Hospital
Hypertension
Physical Exercise in Hypertension, Randomised Clinical Trial
Endurance training has a documented effect on hypertension. However, only low to moderate training intensity has so far been studied.
- Trial name
- NCT00218972
- Testing
- Aerobic interval training, moderate intensity training, Recommendation of regular exercise
- Where
- Norway
- Volunteers
- 88 people
- Sponsor
- Norwegian University of Science and Technology
Essential Hypertension
Olmesartan in Essential Hypertension
To test the efficacy and safety of olmesartan in patients with essential hypertension.
- Trial name
- NCT00185172
- Testing
- olmesartan medoxomil, olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets
- Where
- 8 sites in Austria, Germany and 6 more
- Volunteers
- 2,333 people
- Sponsor
- Sankyo Pharma Gmbh